King Luther Capital Management Corp Acquires 52,945 Shares of Cellebrite DI Ltd. $CLBT

King Luther Capital Management Corp lifted its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 17.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 354,184 shares of the company’s stock after purchasing an additional 52,945 shares during the period. King Luther Capital Management Corp owned about 0.15% of Cellebrite DI worth $6,386,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in the company. CWM LLC boosted its position in Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after buying an additional 889 shares during the period. SkyView Investment Advisors LLC boosted its position in Cellebrite DI by 2.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock valued at $597,000 after buying an additional 970 shares during the period. TD Waterhouse Canada Inc. boosted its position in Cellebrite DI by 2.8% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 54,435 shares of the company’s stock valued at $1,006,000 after buying an additional 1,458 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd boosted its position in Cellebrite DI by 17.8% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 12,216 shares of the company’s stock valued at $220,000 after buying an additional 1,850 shares during the period. Finally, Seelaus Asset Management LLC boosted its position in Cellebrite DI by 11.9% during the 4th quarter. Seelaus Asset Management LLC now owns 18,850 shares of the company’s stock valued at $340,000 after buying an additional 2,000 shares during the period. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Insider Activity at Cellebrite DI

In other news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the sale, the executive directly owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. This trade represents a 2.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 13,269 shares of company stock valued at $169,592. Company insiders own 5.70% of the company’s stock.

Cellebrite DI Trading Down 1.5%

NASDAQ:CLBT opened at $12.70 on Thursday. The company has a 50-day moving average price of $13.29 and a 200-day moving average price of $15.31. Cellebrite DI Ltd. has a 12 month low of $11.02 and a 12 month high of $19.98. The stock has a market cap of $3.17 billion, a price-to-earnings ratio of 45.36, a P/E/G ratio of 1.54 and a beta of 1.15.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CLBT. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Needham & Company LLC dropped their price target on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. DA Davidson began coverage on shares of Cellebrite DI in a research report on Wednesday. They set a “buy” rating and a $20.00 price target for the company. Finally, Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.40.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.